Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort

被引:39
作者
Carr, Daniel F. [1 ]
la Porte, Charles J. L. [2 ,3 ]
Pirmohamed, Munir [1 ]
Owen, Andrew [1 ]
Cortes, Claudia P. [4 ,5 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[2] Univ Ottawa, Ottawa, ON, Canada
[3] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Univ Chile, Sch Med, Santiago, Chile
[5] Fdn Arriaran, Santiago, Chile
关键词
antiretrovirals; pharmacokinetics; genetics; single nucleotide polymorphisms; INFECTED PATIENTS; INDIVIDUALS; EMTRICITABINE; POLYMORPHISMS; METABOLISM;
D O I
10.1093/jac/dkq260
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Efavirenz is extensively metabolized by CYP2B6, and associations between CYP2B6 polymorphisms and plasma efavirenz exposure have been reported. The objective of this study was to investigate CYP2B6 haplotype structure and functional consequences in a Latin American population. Two hundred and nineteen patients were recruited at Fundacion Arriaran, Chile, between September and December 2008. Plasma efavirenz concentrations were determined using liquid chromatography with mass spectrometry. Genotyping for 30 single nucleotide polymorphisms (SNPs) with a minor allele frequency of > 0.05 in the HapMap CEU population at intervals of similar to 1 kb across the CYP2B6 locus was conducted using Sequenom iPLEX MALDI-TOF. Thirteen SNPs passed quality control and, of these, statistically significant associations (P < 0.001) with plasma efavirenz concentrations were observed for 11. Pairwise tagging SNP analysis (R(2) > 0.8) identified 3 SNPs (rs10403955, rs2279345 and rs8192719) representative of the 11 associated SNPs. A composite genetic model of these three alleles was constructed, and an association between carriers of four to six of these alleles and the risk of efavirenz plasma concentrations > 4 mu g/mL was identified with an odds ratio of 48.1 (95% confidence interval: 13.5-207.7). This represents a positive predictive value of 80.9% and a negative predictive value of 91.8%, with sensitivity of 57.9% and specificity of 97.2%. A composite genetic model of CYP2B6 SNPs in a Chilean HIV-positive cohort may have value in predicting concentrations of efavirenz associated with a higher likelihood of CNS toxicity. Further investigation of the functional basis of these associations is now required.
引用
收藏
页码:1889 / 1893
页数:5
相关论文
共 13 条
[1]   Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals [J].
Arab-Alameddine, M. ;
Di Iulio, J. ;
Buclin, T. ;
Rotger, M. ;
Lubomirov, R. ;
Cavassini, M. ;
Fayet, A. ;
Decosterd, L. A. ;
Eap, C. B. ;
Biollaz, J. ;
Telenti, A. ;
Csajka, C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) :485-494
[2]   Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis [J].
Arribas, Jose R. ;
Pozniak, Anton L. ;
Gallant, Joel E. ;
DeJesus, Edwin ;
Gazzard, Brian ;
Campo, Rafael E. ;
Chen, Shan-Shan ;
McColl, Damian ;
Holmes, Charles B. ;
Enejosa, Jeffrey ;
Toole, John J. ;
Cheng, Andrew K. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) :74-78
[3]   In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function [J].
di Iulio, Julia ;
Fayet, Aurelie ;
Arab-Alameddine, Mona ;
Rotger, Margalida ;
Lubomirov, Rubin ;
Cavassini, Matthias ;
Furrer, Hansjakob ;
Guenthard, Huldrych F. ;
Colombo, Sara ;
Csajka, Chantal ;
Eap, Chin B. ;
Decosterd, Laurent A. ;
Telenti, Amalio .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (04) :300-309
[4]   Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV [J].
Gallant, JE ;
DeJesus, E ;
Arribas, JR ;
Pozniak, AL ;
Gazzard, B ;
Campo, RE ;
Lu, B ;
McColl, D ;
Chuck, S ;
Enejosa, J ;
Toole, JJ ;
Cheng, AK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) :251-260
[5]   Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans [J].
Haas, David W. ;
Gebretsadik, Tebeb ;
Mayo, Gail ;
Menon, Usha N. ;
Acosta, Edward P. ;
Shintani, Ayumi ;
Floyd, Michael ;
Stein, C. Michael ;
Wilkinson, Grant R. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (06) :872-880
[6]   CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients [J].
Kwara, Awewura ;
Lartey, Margaret ;
Sagoe, Kwamena W. ;
Rzek, Naser L. ;
Court, Michael H. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (04) :427-436
[7]   Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma [J].
Lorello, G. ;
la Porte, C. ;
Pilon, R. ;
Zhang, G. ;
Karnauchow, T. ;
MacPherson, P. .
HIV MEDICINE, 2009, 10 (09) :548-554
[8]   Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].
Marzolini, C ;
Telenti, A ;
Decosterd, LA ;
Greub, G ;
Biollaz, J ;
Buclin, T .
AIDS, 2001, 15 (01) :71-75
[9]   CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India [J].
Ramachandran, Geetha ;
Kumar, A. K. Hemanth ;
Rajasekaran, Sikhamani ;
Kumar, P. ;
Ramesh, K. ;
Anitha, S. ;
Narendran, G. ;
Menon, Pradeep ;
Gomathi, C. ;
Swaminathan, Soumya .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :863-868
[10]   Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals [J].
Rotger, M. ;
Tegude, H. ;
Colombo, S. ;
Cavassini, M. ;
Furrer, H. ;
Decosterd, L. ;
Blievernicht, J. ;
Saussele, T. ;
Guenthard, H. F. ;
Schwab, M. ;
Eichelbaum, M. ;
Telenti, A. ;
Zanger, U. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :557-566